This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stretcher, B N Articles by Stein, D S Search for Related Content PubMed PubMed Citation Articles by Stretcher, B N Articles by Stein, D S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 July; 38(7): 1541-1547

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.

Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Ohio 45267-0714.

ABSTRACT

As part of an effort towards optimization of dosing of zidovudine (ZDV), formation and elimination of total phosphorylated ZDV (ZDVPt) in peripheral blood mononuclear cells were examined in 21 asymptomatic human immunodeficiency virus-infected patients during their first 24 weeks of therapy (AIDS Clinical Trials Group Protocol 161). Intracellular concentrations of ZDVPt were measured with a previously described and validated radioimmunoassay technique. Although ZDV phosphorylation occurred readily upon initiation of therapy, it declined with time; the area under the concentration-time curve (AUC) at week 4 (mean +/- standard deviation, 3.41 +/- 0.93 pmol.h/10(6) cells) was significantly greater than that at week 24 (2.19 +/- 1.10 pmol.h/10(6) cells). Plasma ZDV AUC did not change with time and did not correlate with ZDVPt AUC. In dose-response experiments (20 to 100 mg orally), phosphorylation did not proportionally increase with increasing plasma ZDV concentrations. Similarly, compared with a single dose, two doses of ZDV over an 8-h period resulted in little ZDVPt increase in cells relative to increase in plasma ZDV concentrations. The half-life of intracellular ZDVPt was twice that of plasma ZDV (4 versus 2 h), suggesting that an every-8-h dosing regimen is justifiable. These findings suggest that metabolism of ZDV to its active intracellular forms may be saturable in some patients, is poorly correlated with plasma concentrations, and diminishes over time. These findings have implications for future development and management of anti-human immunodeficiency virus nucleoside therapy.

This article has been cited by other articles:

• Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F. (2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother. 52: 4241-4250 [Abstract] [Full Text]  
• Anderson, P. L., King, T., Zheng, J.-H., MaWhinney, S. (2008). Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. J Antimicrob Chemother 62: 738-745 [Abstract] [Full Text]  
• van Praag, R. M. E., van Weert, E. C. M., van Heeswijk, R. P. G, Zhou, X.-J., Sommadossi, J.-P., Jurriaans, S., Lange, J. M. A., Hoetelmans, R. M. W., Prins, J. M. (2002). Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy. Antimicrob. Agents Chemother. 46: 896-899 [Abstract] [Full Text]  
• Chow, H.-H., Li, P., Brookshier, G., Tang, Y. (1997). In Vivo Tissue Disposition of 3'-Azido-3'-deoxythymidine and Its Anabolites in Control and Retrovirus-Infected Mice. Drug Metab. Dispos. 25: 412-422 [Abstract] [Full Text]